NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 03/30/2020 12:12
Last Report Issued 10/01/2007 03:48

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 1968B-POS
Patient ID 1968B-POS
Chain 1
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 07000967

Received 05/11/2007 10:25

Sample ID 07000967-001
Matrix Blood
Patient Name 1968B-POS
Patient ID 1968B-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes Not frozen as required

Analysis and Comments	Result	Units	Reporting Limit	Notes
1968B Eszopiclone/Zopiclone, Blood				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Eszopiclone/Zopiclone	5000	ng/mL	2.0	
Synonym(s): Lunesta®; Imovane®				
Once daily 3 mg oral dose given to healthy adults for 7 days resulted in peak serum concentrations of 20 to 33 ng/mL.				
Once daily 2 mg Eszopiclone oral dose given to elderly adults for 7 days resulted in a peak serum concentration of approximately 15 ng/mL.				
This test is not chiral specific; therefore, Eszopiclone and/or Racemic Zopiclone (not approved in the US) may be present.				

Sample receipt condition is inappropriate for test code: Not frozen as required

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.